Abstract
Chordomas are rare, slow-growing neoplasms, characterized by locally aggressive growth patterns and high local recurrence rates. To the best of our knowledge, the MGMT promoter methylation status has not been studied in a population of patients with chordomas to determine if a biologic rationale exists to support the use of temozolomide. We here show for the first time that methylation of MGMT promoter is present in a significant portion or recurring clival chordomas; on the contrary in clival chordomas without recurrence MGMT promoter was always unmethylated (p = 0.0317). Although these observations need to be confirmed in a larger study population, our results (1) indicate that methylation of MGMT promoter is present in a significant portion of recurring chordomas, and (2) prompt further investigation into the potential role of temozolomide as an adjuvant treatment of these tumors.
Original language | English |
---|---|
Pages (from-to) | 271-276 |
Number of pages | 6 |
Journal | Journal of Neuro-Oncology |
Volume | 118 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- Chordoma
- Clivus
- Methylation
- MGMT
- Temozolomide
ASJC Scopus subject areas
- Clinical Neurology
- Cancer Research
- Oncology
- Neurology
- Medicine(all)